Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from AMGN

Dow Hits New High Then Falls 466 Points: Stock Market Today

The Nasdaq Composite, with a little help from tech's friends, rises to within 300 points of its own new all-time high.

Kiplinger

What to Expect From Amgen's Q4 2025 Earnings Report

Amgen will release its fourth-quarter earnings soon, and analysts anticipate a low double-digit profit dip.

Barchart

3 Healthcare Giants Just Raised Dividends—Here’s Who Pays the Most

Healthcare behemoths, including the biggest name of them all, are increasing their dividends. Additionally, AMGN's dividend yield now sits solidly above 3%.

MarketBeat

From analysis to the latest developments in health,
read the most diverse news in one place.

Amgen Stock: New All-Time Highs Ahead After Earnings Beat

Amgen stock jumps after a strong beat-and-raise quarter, pushing shares near split-adjusted all-time highs and signaling more upside ahead

MarketBeat

Stocks Rally as Investors Buy the Dip: Stock Market Today

Most sectors are "go" only a day after talk of bubbles, extended valuations and narrow breadth undermined any kind of exuberance.

Kiplinger

Amgen Stock: Analyst Estimates & Ratings

Amgen stock has been underperforming the broader market over the past year, and analysts are adopting a cautiously bullish stance.

Barchart

The Saturday Spread: Using Data Science to Find Call Spreads Priced in Your Favor

It’s already difficult enough when you step into the world of options. Here’s how to even up the odds against the big dogs.

Barchart

Read news from The Economist, FT, and more,
with one subscription

Here's What to Expect From Amgen’s Next Earnings Report

Amgen is scheduled to report its third-quarter earnings next month, and analysts forecast a modest single-digit decline in profits.

Barchart

Amgen To Offer Cholesterol Drug At 60% Discount As Trump Administration's Call To Lower Drug Prices

Amgen Inc. (NASDAQ:AMGN) on Monday launched AmgenNow, a new direct-to-patient program starting with Repatha (evolucumab).

Benzinga

The Saturday Spread: 3 Beaten-Down Stocks Making a Statistical Case for a Comeback

Here’s an innovative approach to deciphering which red-stained stocks are actually worth a look for bullish contrarians.

Barchart

Amgen Expands US Manufacturing Network Amid New Tariff Policy

Just when the Trump administration announced a 100% tariff on pharmaceuticals starting in October, Amgen Inc (NASDAQ: AMGN) announced a $650 million expansion of its U.S. manufacturing network.

Benzinga

European Advisory Panel Recommends Two AstraZeneca Drugs For Approval

AstraZeneca Plc (NASDAQ:AZN) and Amgen Inc.'s (NASDAQ:AMGN) Tezspire (tezepelumab) has been recommended for approval in the European Union (EU) for adult patients with chronic rhinosinusitis with nasal polyps (CRSwNP).

Benzinga

EMA Backs Amgen Drug For Rare Autoimmune Disorder

The European Medicines Agency’s (EMA) human medicines committee (CHMP) has recommended extending the therapeutic indication of Amgen Inc.’s (NASDAQ:AMGN) Uplizna (inebilizumab) to include the treatment of adult patients with active immunoglobulin G4-related disease (IgG4-RD).

Benzinga

Amgen Rocatinlimab's Data Shows Potential As Long-Term Therapy For Atopic Dermatitis

Amgen Inc. (NASDAQ:AMGN) and Kyowa Kirin released preliminary topline results from the ASCEND study evaluating rocatinlimab in adults and adolescents with moderate to severe atopic dermatitis (AD) on Tuesday.

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Amgen Faces Setback As Final Data Weakens Case For Gastric Cancer Drug

On Wednesday, Amgen Inc. (NASDAQ:AMGN) and its partner Zai Lab (NASDAQ:ZLAB) said the final analysis of the Phase 3 FORTITUDE-101 trial evaluating bemarituzumab in combination with chemotherapy (mFOLFOX6) in first-line gastric cancer has been completed.

Barchart

Is Amgen Stock Underperforming the S&P 500?

Analysts continue to favor Amgen stock, despite its relative underperformance to the broader S&P 500 Index.

Benzinga

BeOne Cashes In On Amgen's Cancer Drug Royalties In Multibillion-Dollar Pharma Tie-Up

BeOne Medicines Ltd. (NASDAQ:ONC) on Monday agreed to sell its royalty rights on the worldwide sales, excluding China, of Amgen Inc.’s (NASDAQ:AMGN) Imdelltra (tarlatamab-dlle) for up to $950 million to Royalty Pharma Inc. (NASDAQ:RPRX).

Benzinga

Amgen Stock Sinks As Market Eyes MariTide's Next Move

Amgen Inc. (NASDAQ:AMGN) shares are trading lower on Wednesday, despite the company reporting second-quarter results that surpassed analyst expectations after markets closed on Tuesday.

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

RFK Jr. Sued By Eli Lilly, Amgen Over Drug Discount Program

Three major pharmaceutical companies — Amgen Inc. (NASDAQ:AMGN), Eli Lilly and Co (NYSE:LLY), and UCB SA (OTC:UCBJY) (OTC:UCBJF) — are suing U.S. Secretary of Health and Human Services (HHS) Robert F. Kennedy Jr. over the way his department is handling a drug discount program.

Benzinga

Amgen Delivers Beat And Raise Quarter; Has Strong Late-Stage Pipeline

Amgen Inc‘s (NASDAQ:AMGN) second quarter results demonstrate ongoing development of its late-stage pipeline “to offset end-of-decade losses-of-exclusivity," according to Goldman Sachs.

Barchart

Do Wall Street Analysts Like Amgen Stock?

Amgen has notably outpaced the broader market and the healthcare sector in 2025, and analysts remain cautiously optimistic about the stock’s prospects.

Barchart

Earnings Preview: What to Expect From Amgen’s Report

Amgen is set to release its second-quarter earnings next month, and analysts are projecting modest single-digit growth in profit.

Benzinga

Amgen (AMGN) Stock Falls After Mixed MariTide Trial Update

Amgen Inc (NASDAQ:AMGN) shares are trading lower by 5.7% to $272.88 Monday afternoon after the company released full results from part one of its phase two study of MariTide, its investigational obesity treatment.

Barchart

How Is Amgen's Stock Performance Compared to Other Pharmaceuticals Stocks?

Amgen has underperformed the Pharmaceuticals industry over the past year, but analysts are moderately optimistic about the stock’s prospects.

Barchart

Amgen Stock Outlook: Is Wall Street Bullish or Bearish?

Although Amgen has lagged behind the broader market over the past year, Wall Street analysts remain cautiously optimistic about the company’s long-term outlook.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

the Trump Administration

Health and Human Services

252 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.